NLS Pharmaceutics Ltd. announced that 90% of the 60 patients required to complete its Phase 2a clinical trial for Quilience (Mazindol ER) have been randomized and the Company continues to expect to report final results from this ground-breaking trial by mid-Q3 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1684 USD | -5.61% |
|
-37.65% | -71.45% |
1st Jan change | Capi. | |
---|---|---|
-71.45% | 6.76M | |
+38.36% | 52.73B | |
+38.59% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- NLSP Stock
- News NLS Pharmaceutics AG
- NLS Pharmaceutics AG Achieves 90% Enrollment Milestone in Quilience® Phase 2a Clinical Trial for Patients with Narcolepsy